Two Sigma Advisers
PDLI

Two Sigma Advisers’s PDL BioPharma, Inc. PDLI Stock Holding History

Two Sigma Advisers’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-89,269
Closed -$290K – 2665
2019
Q4 		$290K Sell
89,269
-379,221
-81% -$1.1M ﹤0.01% 2078
2019
Q3 		$1.01M Sell
468,490
-140,400
-23% -$375K ﹤0.01% 1428
2019
Q2 		$1.91M Sell
608,890
-11,400
-2% -$37K ﹤0.01% 1228
2019
Q1 		$2.31M Sell
620,290
-21,100
-3% -$71.2K 0.01% 1160
2018
Q4 		$1.86M Sell
641,390
-43,303
-6% -$119K 0.01% 1198
2018
Q3 		$1.8M Buy
684,693
+9,600
+1% +$23.6K ﹤0.01% 1278
2018
Q2 		$1.58M Sell
675,093
-70,500
-9% -$197K ﹤0.01% 1407
2018
Q1 		$2.19M Sell
745,593
-143,100
-16% -$391K 0.01% 1208
2017
Q4 		$2.44M Sell
888,693
-51,900
-6% -$159K 0.01% 1154
2017
Q3 		$3.19M Buy
940,593
+88,538
+10% +$246K 0.01% 994
2017
Q2 		$2.1M Sell
852,055
-106,238
-11% -$244K 0.01% 1181
2017
Q1 		$2.17M Sell
958,293
-63,381
-6% -$140K 0.01% 1212
2016
Q4 		$2.17M Buy
1,021,674
+58,362
+6% +$163K 0.01% 1133
2016
Q3 		$3.23M Sell
963,312
-91,800
-9% -$291K 0.01% 824
2016
Q2 		$3.31M Sell
1,055,112
-372,700
-26% -$1.24M 0.02% 687
2016
Q1 		$4.75M Sell
1,427,812
-58,420
-4% -$182K 0.03% 517
2015
Q4 		$5.26M Buy
1,486,232
+104,942
+8% +$439K 0.03% 431
2015
Q3 		$6.99M Sell
1,381,290
-88,207
-6% -$505K 0.04% 392
2015
Q2 		$9.45M Sell
1,469,497
-31,012
-2% -$208K 0.07% 313
2015
Q1 		$10.6M Buy
1,500,509
+983,000
+190% +$7.12M 0.08% 300
2014
Q4 		$3.99M Sell
517,509
-333,900
-39% -$2.64M 0.03% 556
2014
Q3 		$6.36M Sell
851,409
-68,100
-7% -$632K 0.05% 414
2014
Q2 		$8.9M Sell
919,509
-464,100
-34% -$4.14M 0.07% 315
2014
Q1 		$11.5M Buy
1,383,609
+249,500
+22% +$2.14M 0.1% 205
2013
Q4 		$9.57M Sell
1,134,109
-640,800
-36% -$5.4M 0.09% 236
2013
Q3 		$14.1M Buy
1,774,909
+371,854
+27% +$2.99M 0.17% 132
2013
Q2 		$10.8M Buy
+1,403,055
New +$10.9M 0.15% 123

Other funds holding PDLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SPC
Silver Point Capital Greenwich, Connecticut $1.3B AUM 18.3% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
ECM
Engine Capital Management New York $828M AUM 6.49% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Two Sigma Advisers's PDLI Position: Q1 2020 in Review

Two Sigma Advisers sold out of PDL BioPharma, Inc. (PDLI) in Q1 2020, closing a stake of 89,269 shares — an estimated $290K sold.

Two Sigma Advisers first reported a position in PDLI in Q2 2013 and held it in 27 quarters. The position peaked at $14.1M in Q3 2013. 133 funds tracked by Wall St. Rank hold PDLI as of Q1 2020.

  • Two Sigma Advisers reported no remaining PDL BioPharma, Inc. position as of Q1 2020 after selling out during the quarter.
  • Two Sigma Advisers sold 89,269 PDL BioPharma, Inc. shares in Q1 2020, an estimated $290K.
  • Two Sigma Advisers first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 27 quarters.
  • Two Sigma Advisers's PDL BioPharma, Inc. position peaked at $14.1M in Q3 2013.
  • 133 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2020.

Based on Two Sigma Advisers's 13F filing for Q1 2020, filed 15 May 2020.